Back to News
Market Impact: 0.25
Ocugen Expands OCU400 Gene Therapy Reach With $255 Mln Milestone Deal
Source: Nasdaq
Healthcare & BiotechM&A & Restructuring
Ocugen entered an exclusive licensing agreement with Roots Pharmaceutical and its strategic partner, Al-Dhow International Holding, for OCU400. The available article text is truncated and provides no financial terms, territory details, or further description of the investigational product.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
OCGN0.55
More News
- UBS considers leaving Switzerland over capital rule plans, WSJ reports
- Bending Spoons skyrockets 35% as Berkshire Hathaway makes $330 million investment
- Bending Spoons Stock Soars on Berkshire’s Increased Stake
- Ambani’s Jio seeks to raise $3.2B in what could be India’s biggest IPO
- Travis Kelce joined an activist group pushing Six Flags to consider a sale. The ‘Final Destination’-style death of a patron poured gas on the fire
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make